This is a news story, published by Ars Technica, that relates primarily to Adderall news.
For more Adderall news, you can click here:
more Adderall newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Adderall. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Global prescriptions news, stimulant medications news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
ADHD medicationsArs Technica
•
69% Informative
A federal indictment of an allegedly fraudulent telehealth company may lead to a massive disruption in access to ADHD medications.
The CDC warns that the disruption could increase the risk of injuries and overdoses.
The Justice Department announced Thursday that two people were arrested in connection with an alleged scheme to illegally distribute Adderall and other stimulants.
VR Score
58
Informative language
52
Neutral language
35
Article tone
formal
Language
English
Language complexity
77
Offensive language
likely offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links